Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Olmesartan Medoxomil). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Olmevas 40 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage must be individualized. The usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have a greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily. No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance <40 ml/min) or with moderate to marked hepatic dysfunction. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function), Olmesartan should be initiated under close medical supervision and consideration should be given to use of a lower starting dose. Olmesartan may be administered with or without food.Paediatric use: Safety and effectiveness in paediatric patients have not been established.
Side Effects
Oltan's safety was assessed in more than 3825 patients and subjects, including more than 3275 patients treated for hypertension in controlled trials. Treatment with Oltan was well tolerated, and the rate of adverse reactions was similar to placebo. The frequency of adverse reactions did not vary by dose. Looking at gender, age and race groups, no differences turned up between patients treated with Oltan and those given placebo. Across all hypertension trials, 2.4% of patients treated with Oltan withdrew due to adverse reactions, compared with 2.7% of control patients. In placebo controlled trials, the only adverse reaction affecting more than 1% of patients treated with Oltan, at a higher rate than placebo, was dizziness (3% vs. 1%). The following adverse reactions occurred in placebo controlled clinical trials in more than 1% of patients treated with Oltan, but at a similar or greater rate among patients given placebo: back pain, bronchitis, increased creatine phosphokinase, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza like symptoms, pharyngitis, rhinitis and sinusitis. Cough occurred at a similar rate in placebo treated patients (0.7%) and Oltan treated patients (0.9%).
Cautions & Contraindications
Warnings & Precautions
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with Oltan. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (for example, patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and, rarely, with acute renal failure and/or death. Similar results may be anticipated in patients treated with Oltan.
Contraindications
Olmesartan medoxomil should not be used by anyone who has previously had an allergic reaction to it or to any other ingredient in this medicine.